research Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy
DPCP may be safe for treating alopecia during pregnancy, but more research is needed.
Search
for
Sort by
Research
60-90 / 1000+ resultsresearch Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients
Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.
research Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa
PSENEN gene mutations can cause both Dowling-Degos disease and acne inversa.
research Biological activity and hair inducing function of biomimetic dermal papilla spheres prepared by hanging drops of methacrylate gelatin
Biomimetic dermal papilla spheres can help regenerate hair to some extent.
research DSP c.6310delA p.(Thr2104Glnfs*12) associates with arrhythmogenic cardiomyopathy, increased trabeculation, curly hair, and palmoplantar keratoderma
A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.
research Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.
research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
Post-drug syndromes are often overlooked, and better systems and education are needed to improve drug safety.
research USO DE ESTIMULAÇÃO CEREBRAL PROFUNDA (DBS) PARA O TRATAMENTO DA DOENÇA DE PARKINSON
Deep Brain Stimulation helps manage Parkinson's symptoms when medication isn't enough.
research Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone
Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.
research Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin
DPCP alone is more effective and safer for treating chronic extensive alopecia areata than combining it with anthralin.
research Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells
PGD2 increases androgen receptor activity in hair cells, which could be targeted to treat hair loss.
research Clinical efficacy of diphenylcyclopropenone in alopecia areata: Retrospective data analysis of 50 patients
Diphenylcyclopropenone (DPCP) is effective in treating alopecia areata, with most patients showing significant hair regrowth.
research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
Current drug safety systems fail to detect long-term side effects, needing improvements to protect health and trust.
research RAPID ANALYSIS OF FINASTERIDE IN BULK AND FORMULATIONS BY RP-HPLC-PDA METHOD
New method accurately measures finasteride in tablets and bulk.
research Topical Immunotherapy with Diphenylcyclopropenone in Paediatric Patients with Alopecia Areata—A Retrospective Study of 97 Patients
Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.
research Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata
Home-use treatment for severe alopecia areata is as effective as office-use but costs half as much.
research Severe dermographism after topical therapy with diphenylcyclopropenone for alopecia universalis
A man developed severe skin reactions after using a treatment for hair loss.
research 560 The molecular mechanism of PCE-DP, a novel brightening active ingredient
PCE-DP brightens skin and promotes hair growth by enhancing cell growth and reducing melanin uptake.
research A reasonable Response to Diphensiprone in Pediatric Alopecia Patient: A Case Report
Topical diphencyprone effectively treated a 9-year-old boy's alopecia areata with fewer side effects.
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
research Efficacy of topical diphenylcyclopropenone maintenance treatment for patients with alopecia areata: A retrospective study
Diphenylcyclopropenone treatment helps prevent hair loss relapse in alopecia areata patients.
research Dissolving microneedle array patches containing mesoporous silica nanoparticles of different pore sizes as a tunable sustained release platform
Dissolving microneedle patches can effectively deliver drugs over time.
research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
research 54675 Organizations to Assist Patients in Accessing Prescription Assistance Programs for Dermatology Medications
Organizations help patients access discounts for expensive dermatology medications.
research Administration of dutasteride in animal models of retinitis pigmentosa
Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
research Regulation of immune response genes in the skin of allergic and clinically tolerant individuals exposed to p‐phenylenediamine
Everyone has an immune response to PPD, but reactions differ, causing tolerance, mild inflammation, or allergy.
research THE HEART OF IT ALL: DILATED CARDIOMYOPATHY AS THE INITIAL PRESENTATION OF ANTIPHOSPHOLIPID SYNDROME
Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
research Alopecia Areata: An Overview
DPCP works best for alopecia areata, but more research is needed for better treatments.
research A Hairy Cituation – PADIs in Regeneration and Alopecia
Enzymes called PADIs play a key role in hair growth and loss.
research 42175 PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials
Guselkumab significantly improves psoriasis symptoms within 12 weeks.